BLVIS A Blue Vision A

Pharma Equity Group 2025 Financial Calendar

Pharma Equity Group 2025 Financial Calendar

14 January 2025

News Release

 



Pharma Equity Group

2025 Financial Calendar



 
​March 4Deadline for shareholder proposals - Annual General meeting​



 
​March 20 ​Annual Report 2024​



 
April 16Annual General Meeting​



 
May 15Interim Report – for the three-month period ended March 31, 2025​



 
August 14Interim Report – for the six-month period ended June 30, 2025​



 
November 14Interim Report – for the nine-month period ended September 30, 2025



 

​Contact person – Investor Relations

On the Company’s website further information and all published announcements can be found.

Inquiries regarding relations with investors and the stock market can be directed to: Thomas Kaas Selsø, CEO, Phone: E-mail: .

About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.





Attachment



EN
14/01/2025

Underlying

BLVIS ABlue Vision A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Vision A

 PRESS RELEASE
Free
BLVIS A BLUE VISION A

The Board of Directors' resolution on the issuance of convertible loan...

The Board of Directors' resolution on the issuance of convertible loans      The Board of Directors' resolution on the issuance of convertible loans  July 1, 2025Announcement no. 8 The Board of Directors of Pharma Equity Group has decided to issue convertible loans in accordance with the authorisation in the Company's Articles of Association under item 4.3.A. The convertible loans allow Pharma Equity Group to borrow up to DKK 5,842,500. In connection with this issuance, existing convertible loans of DKK 4,817,500 and a utilized credit facility of DKK 1,025,000 will be repaid. Th...

July 1, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Bestyrelsens beslutning om udstedelse af konvertible lån

Bestyrelsens beslutning om udstedelse af konvertible lån       Bestyrelsens beslutning om udstedelse af konvertible lån  1. juli 2025Meddelelse nr. 8   Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af konvertible lån i henhold til bemyndigelsen i selskabets vedtægter under pkt. 4.3.A. De konvertible lån giver Pharma Equity Group mulighed for at låne op til DKK 5.842.500. I forbindelse hermed indfris tidligere udstedte konvertible lån for DKK 4.817.500 samt en udnyttet kreditramme på DKK 1.025.000. Hovedvilkårene for de konvertible lån på DKK 5.842.500 er:  Lånene er...

July 1, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group A/S lancerer ny strategi for at accelerere vækst o...

Pharma Equity Group A/S lancerer ny strategi for at accelerere vækst og skabe værdi for aktionærerne      Pharma Equity Group A/S lancerer ny strategi for at accelerere vækst og skabe værdi for aktionærerne 28. maj 2025Selskabsmeddelelse nr. 7 Pharma Equity Group (PEG) offentliggør i dag lanceringen af en ny, transformerende investeringsstrategi, der har til formål at accelerere vækst, diversificere selskabets portefølje inden for lægemidler og medicinsk udstyr, herunder MedTech, samt øge det langsigtede afkast til aktionærerne. En central del af strategien er den planlagte etablering af ...

May 28, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group A/S Launches New Strategy to Drive Growth and Shar...

Pharma Equity Group A/S Launches New Strategy to Drive Growth and Shareholder Returns      Pharma Equity Group A/S Launches New Strategy to Drive Growth and Shareholder Returns 28 May 2025Announcement no. 7  Pharma Equity Group (PEG) today announces the launch of a transformative investment strategy aimed at accelerating growth, diversifying its portfolio across Pharma and Medical Devices, including MedTech, and enhancing long-term shareholder returns. Central to this strategic launch is the contemplated establishment of a dedicated Investment Committee (IC) to ensure rigorous...

May 28, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Forløb af generalforsamlingen i Pharma Equity Group A/S

Forløb af generalforsamlingen i Pharma Equity Group A/S      Forløb af generalforsamlingen i Pharma Equity Group A/S  05. maj 2025Selskabsmeddelelse nr. 6 Pharma Equity Group A/S har 16 april 2025 afholdt ordinær generalforsamling med følgende resultat:  Dirigenten gennemgik dagsordenen for dagens generalforsamling, som var: Bestyrelsens beretning om Selskabets virksomhed det forløbne årFremlæggelse af revideret årsrapport til godkendelseMeddelelse af decharge for bestyrelsen og direktionenVedtagelse af fordeling af overskud eller underskud efter forslag fra bestyrelsenFremlæggelse af v...

May 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch